139693-52-0

Usage

Uses

Used in Pharmaceutical Industry:
6-cyclopropyl-8,9-difluoro-7-methoxy-4-oxo-4,6-dihydro-2H-1l3-[1,3]dioxino[5,6-c]quinoline-2,2-diyl diacetate is used as a potential pharmaceutical compound for its in vitro antibacterial activity. The compound is studied for its ability to inhibit bacterial growth, making it a candidate for the development of new antibiotics to combat drug-resistant bacteria.
Used in Chemical Research:
In the field of chemical research, 6-cyclopropyl-8,9-difluoro-7-methoxy-4-oxo-4,6-dihydro-2H-1l3-[1,3]dioxino[5,6-c]quinoline-2,2-diyl diacetate can be used as a starting material or intermediate in the synthesis of other complex organic molecules. Its unique structure may provide insights into the development of new chemical reactions and methodologies.
Used in Material Science:
The compound's specific properties, such as its fluorinated and cyclopropyl groups, may make it suitable for use in the development of new materials with unique characteristics. It could potentially be utilized in the creation of advanced materials for various applications, including electronics, coatings, or adhesives.

Upstream product

• 108-24-7 acetic anhydride 
• 112811-71-9 ethyl 8-methoxy-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate 
• 112811-72-0 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 
• 11113-50-1 boric acid 
• 1103242-32-5 boron trioxide 
• 4887-24-5 triacetoxyborane 

Downstream Products

• 186826-86-8 moxifloxacin hydrochloride 
• 1446946-23-1 7-[3-amino-4-(4'-bromo-2'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-25-3 7-[3-amino-4-(2',5'-dimethoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-26-4 7-[3-amino-4-(3',5'-dimethoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-27-5 7-[3-amino-4-(2',3'-dimethoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-28-6 7-[3-amino-4-(3',4'-dimethoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-30-0 7-[3-amino-4-(2'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-31-1 7-[3-amino-4-(3'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-32-2 7-[3-amino-4-(4'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-33-3 7-[3-amino-4-(4'-fluorobenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-34-4 7-[3-amino-4-(4'-chlorobenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-35-5 7-(3-amino-4-benzyloxyiminopiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1394029-14-1 moxifloxacin hydrochloride 
• 172426-88-9 7-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Synthesis method of moxifloxacin hydrochloride oxide impurity

The invention relates to a synthesis method of a moxifloxacin hydrochloride oxide impurity as shown in a formula I-1. The method comprises the following steps: step 1) reacting a compound I-5 with a compound I-4 to obtain a compound I-6; and 2) removing a protecting group from the compound I-6 prepared in the step 1) under an acidic condition to obtain a compound I-1, namely the moxifloxacin hydrochloride oxide impurity.

Preparation method of moxifloxacin hydrochloride

The invention discloses a preparation method of moxifloxacin hydrochloride, and the preparation method comprises the following steps: (1) preparing 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid-O3,O4-boron diacetate, and (2) carrying out a reaction on the 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid-O3,O4-boron diacetate; (2)adding the 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid-O3,O4-boron diacetate and (S,S)-2,8-diazabicyclo[4.3.0]nonane in a solvent in the presence of an acid-binding agent to obtain a borane condensate, removing the solvent, dissolving the borane condensate in water, and adding hydrochloric acid to form salt and crystallize to obtain moxifloxacin hydrochloride. According to the preparation method, the borane condensate is dissolved in water, and hydrochloric acid is added for salifying and crystallizing, so that genotoxic impurities such as chloromethaneand chloroethane are not generated, and an impurity C is not generated; therefore, moxifloxacin hydrochloride prepared by means of the preparation method is high in purity and low in risk.

Preparation method of moxifloxacin hydrochloride (by machine translation)

The invention relates to a preparation method of moxifloxacin hydrochloride. , 1 - Cyclopropyl -7 - (S, S-2, diazabicyclo [4.3.0] nonane -8 - yl) -6 - fluoro -8 - methoxy -4 - oxo -1, 4 - dihydro -3 - quinoline carboxylic acid hydrochloride is prepared. The condensation reaction solvent acetonitrile is recovered after a certain technical means is recovered to form a condensation product borane chelating moxifloxacin, and the condensation reaction solvent acetonitrile can be reused for the condensation reaction step after the condensation reaction solvent acetonitrile is recovered by a certain technical means. The condensate is hydrolyzed with sodium hydroxide solution in acetone, and then pH is adjusted to acid by hydrochloric acid to form a moxifloxacin hydrochloride crude product, and the crude product is refined after refining in a mixture of ethanol and water to obtain refined moxifloxacin hydrochloride. To the method, the condensation reaction temperature is reduced, the product purity is improved, the emission of three wastes is reduced, the production cost is reduced, and the method is suitable for industrial production. (by machine translation)

Preparation method of moxifloxacin hydrochloride

The invention discloses a preparation method of moxifloxacin hydrochloride. The method comprises the following steps: performing condensation by using 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-ethylquinolinecarboxylate as a central ring, and (S,S)-2,8-diazabicyclo[4,3,0]nonane as a side chain, after alkali hydrolysis is completed, adding a part of 6N hydrochloric acid, performing primary crystallization, adding the remaining 6N hydrochloric acid, performing secondary crystallization, and performing recrystallization on the crystallized product obtain by the secondary crystallization once by using ethanol to obtain the moxifloxacin hydrochloride with a high content and excellent quality. When the method provided by the invention is adopted to prepare the moxifloxacin hydrochloride, product loss caused by repeated crystallization is reduced, labor intensity is reduced, energy consumption is reduced, product stability is improved, product quality is greatly improved, and themethod is suitable for industrialized large-scale production; and the prepared moxifloxacin hydrochloride contains 99.6%-102.0% of C21H25ClFN3O4 calculated by an anhydrate, and has a low total impurity content.

Moxifloxacin hydrochloride new preparation method

The invention provides a method for preparing a moxifloxacin intermediate and moxifloxacin hydrochloride, which comprises the following steps: carrying out condensation reaction on main ring chelate disclosed as Formula (I) and (S,S)-2,8-diazabicyclo-[4.3.0]nonane in the presence of an acid acceptor in a solvent, acidifying for salification, crystallizing, filtering, washing and drying to obtain the moxifloxacin hydrochloride. The method is characterized in that the solvent in the condensation reaction is alcohol. The condensation reaction is carried out in the alcohol solvent at the controlled temperature of 30-80 DEG C (preferably lower temperature), so the method has the advantage of mild reaction conditions, greatly reduces the generation of impurities, saves the energy; the alcohol solvent can be directly acidified after sufficient reaction, thereby saving the complex step of removing acetonitrile by evaporation and greatly simplifying the steps; and the method is suitable for industrial production.

Preparation method of high-purity moxifloxacin hydrochloride impurity I

The invention discloses a preparation method of a high-purity moxifloxacin hydrochloride impurity I. The preparation method comprises the following steps: using 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinoline carboxylic acid or ester thereof as a starting raw material; carrying out borate reaction, azido reaction, hydrolysis reaction and reduction reaction to obtain the moxifloxacin hydrochloride impurity I. The impurity I product obtained by the preparation method disclosed by the invention has the advantages of high purity and high yield.

Moxifloxacin of a preparation or a pharmaceutically acceptable salt, wherein the method of the midbody

The invention provides a novel method for preparing moxifloxacin or its medicinal salt and its intermediate, which comprises the following steps: dissolving boron trioxide in a certain amount of acetic anhydride and an acetate mixing solution, reacting under the temperature of 90-120 DEG C, cooling a reaction solution; adding cyclized quinolinecarboxylic ester in the reaction solution and reacting at the reaction temperature of 50-80 DEG C, cooling, adding a certain amount of an ether solvent, stirring and then filtering, washing by the ether solvent, drying to obtain the product; reacting with (4aR, 7aR)-octahydropyrrolo[3,4-b]pyridine to obtain the moxifloxacin or its medicinal salt. The reaction method of the invention is mild and controllable, the common equipments enable production, the obtained product has the advantages of high purity and good color, boron oxide substitutes boric acid for chelating to reduce the damage of equipments and human body caused by acid mist in the reaction.

Preparation method of key intermediate of moxifloxacin

The invention discloses a preparation method of a key intermediate of moxifloxacin. The preparation method includes the steps of (1), filling a reaction kettle A with boracic acid, acetic anhydride and zinc chloride, heating to a reaction temperature and violently stirring to obtain a reactive material liquid; (2), in a reaction process, pumping the reactive material liquid into a continuous disacidifying system filled with a disacidifying agent at a certain flow speed to remove generated acetic acid, and pumping the reactive material liquid into a reaction kettle B; (3), adding 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinoline carboxylic acid into the reaction kettle B with stirring; (4), after reaction is terminated, conducting vacuum concentration, crystallizing and filtering so as to obtain the key intermediate. The preparation method of the key intermediate of the moxifloxacin has the advantages that a continuous disacidifying device is adopted to remove the byproduct acetic acid difficult to distill when boron ester is generated, so that conversion ratio of raw material (S,S)-2,8-diazabicyclo[4,3,0]nonane is increased effectively, yield of a target product I is increased greatly, technological scale-up operability is enhanced and low-energy-consumption continuous production is achieved simply and quickly.

A high-purity hydrochloric acid moxifolxacin method for the synthesis of (by machine translation)

The present invention provides a high-purity hydrochloric acid method for synthesizing moxifolxacin, comprising the following steps: the benzol the 1-cyclopropyl -6,7-difluoro-8-methoxy -1,4-dihydro-4-oxo-quinolyl-3-carboxylic acid ethyl ester carbonyl of protection, then the (S, S) - 2,8-diazabicyclo [4.3.0] nonane after to conduct the condensation reaction, to adopt the hydrochloric acid is deprotected, star thick mozambican Xisha hydrochloric acid obtained; the resulting star thick mozambican Xisha of the hydrochloric acid aqueous solution of alkali is dissolved, then extracting with an organic solvent, removal of the organic phase, the aqueous phase by adding hydrochloric acid to adjust pH in value to acidity, then crystallization, filtering to obtain the filter cake, then the aqueous organic solvent to the obtained filter cake of performing recrystallization, final filtering, drying to obtain high-purity hydrochloric acid Moxifloxacin. The method of the invention high purity of the prepared product, high yield, good reproducibility, has extremely strong the feasibility of industrial operation. (by machine translation)

Preparation method of moxifloxacin impurity G compound

The invention provides a preparation method of a moxifloxacin impurity G compound, comprising using 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxoquinolyl-3-carboxylic acid ethyl ester as a starting material to react with triacetoxyboron, then removing ethyl ester to generate moxifloxacin boron diacetate, reacting with (S,S)-2,8-diazabicyclo[4.3.0]nonane, then removing a protective base and salifying to generate moxifloxacin hydrochloride, oxidizing via an oxidizing agent, and then acquiring moxifloxacin impurity G in the presence of a dewatering agent. The preparation method is simple to perform, a prepared target product has high purity, and an obtained substance is useful for studying moxifloxacin hydrochloride related substances.